Drugs & lymphoma
Drug adverse reactions citations
Bebb
JR, Logan RP. Does the use of immunosuppressive therapy in inflammatory
bowel disease increase the risk of developing lymphoma?Aliment
Pharmacol Ther. 2001 Dec;15(12):1843-9.PMID: 11736713 [PubMed - in process]
Recent case reports have raised concerns regarding the risks of
non-Hodgkin's lymphoma in patients with inflammatory bowel disease treated with
immunosuppressive agents. This evidence-based review examines this issue from data derived
from the use of immunosuppression in other conditions (and inflammatory bowel disease). We
conclude that, in transplant (cardiac and renal) recipients, immunosuppression increases
the risk of non-Hodgkin's lymphoma. For non-transplant patients (with psoriasis and
rheumatoid arthritis), debate remains as to whether the observed increase in the incidence
of non-Hodgkin's lymphoma is due to drug or disease. For inflammatory bowel disease per
se, population studies show no significant increase in the risk of non-Hodgkin's lymphoma,
with a relative risk of 1.3 (95% confidence interval, 0.9-1.7) compared to expected rates,
and several studies of immuno- suppression in inflammatory bowel disease do not appear to
confirm a significant rate of lymphoma incidence. Reported cases of lymphoma from single
centres should be viewed with caution as evidence of increased risk. If any association
exists, it is likely to be of minimal clinical significance compared to the established
and more frequent risks of myelosuppression and infection, and is unlikely to outweigh the
benefit of immunosuppression in inflammatory bowel disease.PMID: 11736713 [PubMed - in
process]
Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate.J Rheumatol. 1991 Nov;18(11):1741-3.PMID: 1787499 [PubMed - indexed for MEDLINE]
Grardel B, Fauquert P, Hardouin P. Malignancy in patients with rheumatoid arthritis treated with methotrexate.J Rheumatol. 1997 Apr;24(4):805-6; discussion 806-7. No abstract available.PMID: 9101525 [PubMed - indexed for MEDLINE]
Kirsner AB, Farber SJ, Sheon RP, Finkel RI. The incidence of malignant disease in patients receiving cytotoxic therapy for rheumatoid arthritis.Ann Rheum Dis. 1982;41 Suppl 1:32-3.PMID: 7065741 [PubMed - indexed for MEDLINE]
Iqbal MP, Ali AA, Alvi AA [corrected to Ali AA]. Severe bone marrow suppression in a patient with rheumatoid arthritis on methotrexate.J Pak Med Assoc. 1993 Dec;43(12):262-3. No abstract available.PMID: 8133640 [PubMed - indexed for MEDLINE]
Omdal R, Goransson L, Bergrem H.Fatal outcome of low-dose methotrexate therapy in rheumatoid arthritis.Clin Rheumatol. 1993 Jun;12(2):283-4. No abstract available.PMID: 8358998 [PubMed - indexed for MEDLINE]
Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W. Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab.Ann Rheum Dis. 2001 Sep;60(9):892-3.